RU2018128464A - Связывающие элементы против pd-l1 - Google Patents
Связывающие элементы против pd-l1 Download PDFInfo
- Publication number
- RU2018128464A RU2018128464A RU2018128464A RU2018128464A RU2018128464A RU 2018128464 A RU2018128464 A RU 2018128464A RU 2018128464 A RU2018128464 A RU 2018128464A RU 2018128464 A RU2018128464 A RU 2018128464A RU 2018128464 A RU2018128464 A RU 2018128464A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- paragraphs
- element according
- connecting element
- binding
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims 27
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims 16
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims 16
- 238000000034 method Methods 0.000 claims 24
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000011541 reaction mixture Substances 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 210000003741 urothelium Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 241000282342 Martes americana Species 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100024554 Tetranectin Human genes 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000010170 biological method Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 108010013645 tetranectin Proteins 0.000 claims 1
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/EP2017/054367 WO2017144681A1 (en) | 2016-02-25 | 2017-02-24 | Binding members to pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018128464A true RU2018128464A (ru) | 2020-03-25 |
Family
ID=55446573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018128464A RU2018128464A (ru) | 2016-02-25 | 2017-02-24 | Связывающие элементы против pd-l1 |
| RU2018128462A RU2018128462A (ru) | 2016-02-25 | 2017-02-24 | Модифицированные клетки для иммунотерапии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018128462A RU2018128462A (ru) | 2016-02-25 | 2017-02-24 | Модифицированные клетки для иммунотерапии |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11434294B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3420001B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7080819B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20180111870A (cg-RX-API-DMAC7.html) |
| CN (3) | CN116082505A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017224843A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112018067696A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3014001A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2903408T3 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2018128464A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201807188VA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2017144681A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| NZ754365A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | Novel t cell receptors and immune therapy using the same |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| EP3555273B1 (en) | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| CN117442719A (zh) | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EA201992586A1 (ru) | 2017-04-28 | 2020-03-03 | Файв Прайм Терапьютикс, Инк. | Способы лечения с помощью полипептидов внеклеточного домена cd80 |
| JP2021507703A (ja) | 2017-12-20 | 2021-02-25 | ポセイダ セラピューティクス，インコーポレイティド | Ｖｃａｒ組成物とその利用法 |
| WO2019141774A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| WO2019166650A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CN117362436A (zh) * | 2018-03-29 | 2024-01-09 | 桂林三金药业股份有限公司 | 抗pd-l1抗体及其用途 |
| US12304963B2 (en) * | 2018-06-04 | 2025-05-20 | Diatheva S.R.L. | Antibody complex and uses thereof |
| US11760983B2 (en) | 2018-06-21 | 2023-09-19 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR102250234B1 (ko) * | 2018-06-29 | 2021-05-10 | 주식회사 와이바이오로직스 | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 |
| CA3105750A1 (en) | 2018-07-09 | 2020-01-16 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| BR112021006254A2 (pt) * | 2018-10-01 | 2021-07-27 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| SG11202103317XA (en) * | 2018-10-17 | 2021-05-28 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| JP7571021B2 (ja) * | 2018-12-06 | 2024-10-22 | グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド | 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| WO2020159941A1 (en) * | 2019-01-28 | 2020-08-06 | Xyphos Biosciences Inc. | Modified non-natural nkg2d ligands that selectively deliver attached heterologous molecules to non-natural nkg2d receptors on car-cells |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| WO2020198531A2 (en) * | 2019-03-26 | 2020-10-01 | The Regents Of The University Of California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN118344479A (zh) * | 2019-06-12 | 2024-07-16 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| CA3141457A1 (en) * | 2019-07-02 | 2021-01-07 | Michael Paul Wheatcroft | Antibodies against caix with reduced affinity for the neonatal fc receptor |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| US20210128710A1 (en) * | 2019-11-04 | 2021-05-06 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN110760007B (zh) * | 2019-11-21 | 2022-08-26 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| AU2020396896A1 (en) * | 2019-12-02 | 2022-06-09 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-L1 and methods of use thereof |
| JP2023515747A (ja) * | 2019-12-28 | 2023-04-14 | シャンハイ セル セラピー グループ カンパニー カンパニー リミテッド | 免疫調節分子を発現する細胞および免疫調節分子を発現するための系 |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| KR20210118759A (ko) * | 2020-03-23 | 2021-10-01 | (주)큐리진 | 이중 특이적 핵산분자를 포함한 항암 바이러스의 구조 |
| KR20230038139A (ko) * | 2020-05-14 | 2023-03-17 | 버투오소 빈코, 인크. | 인간화 cd38 및 icam1 항체 및 이의 용도 |
| CN116209749A (zh) * | 2020-06-11 | 2023-06-02 | 创新细胞治疗控股有限公司 | 靶向mage-a4肽的细胞/基因疗法 |
| WO2021262499A1 (en) * | 2020-06-25 | 2021-12-30 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| AU2021305234A1 (en) | 2020-07-10 | 2023-02-09 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| EP4240380A4 (en) * | 2020-11-04 | 2024-10-16 | Senti Biosciences, Inc. | PROTEIN PAYLOAD RELEASE |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| US20240287147A1 (en) * | 2020-11-30 | 2024-08-29 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| CN118019842A (zh) * | 2021-07-01 | 2024-05-10 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| CN117999364A (zh) | 2021-08-13 | 2024-05-07 | 艾诺奥医药品有限公司 | 用以治疗脑癌的组合疗法 |
| CN118176017A (zh) * | 2021-10-26 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| AU2023213978A1 (en) * | 2022-01-28 | 2024-08-15 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
| CN118005806A (zh) * | 2024-02-08 | 2024-05-10 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| DK1506236T3 (da) | 2002-05-22 | 2013-03-04 | Esbatech A Novartis Co Llc | Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
| NZ596237A (en) | 2006-12-27 | 2012-07-27 | Dana Farber Cancer Inst Inc | Compositions and methods for the treatment of infections and tumors |
| HRP20160730T1 (hr) | 2007-06-25 | 2016-07-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Metode modificiranja antitijela i modificirana antitijela s poboljšanim funkcionalnim svojstvima |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| WO2009155725A1 (en) | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| WO2011066389A1 (en) * | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| EP3326467B1 (en) | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102163408B1 (ko) * | 2012-05-31 | 2020-10-08 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| WO2013182912A2 (en) | 2012-06-06 | 2013-12-12 | Fundacio Privada Institut De Recerca Biomedica | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| EP3811954A1 (en) | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | Novel antibody frameworks |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP2017518053A (ja) * | 2014-06-06 | 2017-07-06 | メモリアル スローン−ケタリング キャンサー センター | メソセリン標的化キメラ抗原受容体およびその使用 |
| US20160009805A1 (en) * | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| AU2015310897B2 (en) | 2014-09-04 | 2020-03-19 | Cellectis | Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| EP3198010B1 (en) | 2014-09-26 | 2020-11-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| SG11201703309PA (en) | 2014-10-31 | 2017-05-30 | Baylor College Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| US20170362297A1 (en) | 2014-12-19 | 2017-12-21 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptors and methods of use thereof |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
-
2017
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja active Active
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja active Active
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018128464A (ru) | Связывающие элементы против pd-l1 | |
| JP7442443B2 (ja) | 多重特異性抗体 | |
| Sawada et al. | Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity | |
| CN111944050B (zh) | 一种抗b7-h3抗体及其应用 | |
| CN111183159B (zh) | 靶向cd137的抗体及其使用方法 | |
| EP4114862A2 (en) | Anti-ccr8 agents | |
| JP2013502913A5 (cg-RX-API-DMAC7.html) | ||
| JP2017186337A5 (cg-RX-API-DMAC7.html) | ||
| JP2012518425A5 (cg-RX-API-DMAC7.html) | ||
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| TW201920282A (zh) | 抗egfr和pd-1的雙特異性抗體 | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2023179450A (ja) | 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途 | |
| KR20210069058A (ko) | 항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도 | |
| EP4628508A1 (en) | Anti-ilt4 antibody as well as preparation method therefor and use thereof | |
| CN111542537A (zh) | 抗cd123抗体及其制备方法和应用 | |
| CN115397860A (zh) | 抗cd25抗体、其抗原结合片段及其医药用途 | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| JP7341060B2 (ja) | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 | |
| CN119176876A (zh) | 抗b7-h4抗体及其应用 | |
| WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| EP4663661A1 (en) | Anti-cdh6 antibody and use thereof | |
| WO2022228431A1 (zh) | 抗pd-l1单域抗体及其用途 | |
| KR102907326B1 (ko) | Cd137을 표적화하는 항체 및 이의 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200225 |